Compare Stocks: AQST, MLYS, PBH, and PRGO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.68 -2.9%	$4.52	$2.93 ▼ $7.55	$587.40M	1.48	2.25 million shs	1.91 million shs
MLYS Mineralys Therapeutics	$25.86 -2.7%	$27.14	$22.30 ▼ $47.65	$2.29B	0.68	1.35 million shs	1.19 million shs
PBH Prestige Consumer Healthcare	$46.51 +1.9%	$50.31	$42.62 ▼ $71.07	$2.21B	0.33	565,986 shs	467,651 shs
PRGO Perrigo	$15.43 +5.1%	$13.03	$9.23 ▼ $22.65	$2.14B	0.59	2.69 million shs	4.27 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+1.52%	-9.30%	+6.61%	-13.65%
MLYS Mineralys Therapeutics	0.00%	-7.71%	-0.58%	-3.07%	-33.47%
PBH Prestige Consumer Healthcare	0.00%	+3.55%	-9.28%	-5.80%	-26.47%
PRGO Perrigo	0.00%	+13.53%	+7.48%	+55.43%	-27.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.68 -2.9%	$4.52	$2.93 ▼ $7.55	$587.40M	1.48	2.25 million shs	1.91 million shs
MLYS Mineralys Therapeutics	$25.86 -2.7%	$27.14	$22.30 ▼ $47.65	$2.29B	0.68	1.35 million shs	1.19 million shs
PBH Prestige Consumer Healthcare	$46.51 +1.9%	$50.31	$42.62 ▼ $71.07	$2.21B	0.33	565,986 shs	467,651 shs
PRGO Perrigo	$15.43 +5.1%	$13.03	$9.23 ▼ $22.65	$2.14B	0.59	2.69 million shs	4.27 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+1.52%	-9.30%	+6.61%	-13.65%
MLYS Mineralys Therapeutics	0.00%	-7.71%	-0.58%	-3.07%	-33.47%
PBH Prestige Consumer Healthcare	0.00%	+3.55%	-9.28%	-5.80%	-26.47%
PRGO Perrigo	0.00%	+13.53%	+7.48%	+55.43%	-27.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.88	Moderate Buy	$9.17	95.87% Upside
MLYS Mineralys Therapeutics	2.50	Moderate Buy	$48.80	88.71% Upside
PBH Prestige Consumer Healthcare	2.00	Hold	$67.67	45.48% Upside
PRGO Perrigo	2.00	Hold	$19.33	25.33% Upside

Current Analyst Ratings Breakdown

Latest AQST, MLYS, PBH, and PRGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	PBH Prestige Consumer Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
9/11/2026	MLYS Mineralys Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/10/2026	AQST Aquestive Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$11.00
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/13/2026	MLYS Mineralys Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/6/2026	PRGO Perrigo	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/21/2026	PRGO Perrigo	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	AQST Aquestive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	MLYS Mineralys Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.09M	10.86	N/A	N/A	($0.28) per share	-16.71
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$8.17 per share	N/A
PBH Prestige Consumer Healthcare	$1.09B	2.02	$5.20 per share	8.95	$39.89 per share	1.17
PRGO Perrigo	$4.14B	0.52	$5.30 per share	2.91	$21.33 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
MLYS Mineralys Therapeutics	-$154.65M	-$4.24	N/A	N/A	N/A	N/A	-57.97%	-54.15%	11/9/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.03	9.14	1.46	15.57%	11.39%	5.66%	11/5/2026 (Estimated)
PRGO Perrigo	-$1.43B	-$12.51	N/A	6.54	1.77	-41.85%	11.25%	4.08%	11/4/2026 (Estimated)

Latest AQST, MLYS, PBH, and PRGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MLYS Mineralys Therapeutics	-$0.5486	-$2.85	-$2.3014	-$2.85	N/A	N/A
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/5/2026	Q2 2026	PRGO Perrigo	$0.3880	$0.50	+$0.1120	$0.53	$1.02 billion	$1.02 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	7.52%	+5.21%	N/A	23 Years

Latest AQST, MLYS, PBH, and PRGO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	PRGO Perrigo	quarterly	$0.29	7.98%	8/28/2026	8/28/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
MLYS Mineralys Therapeutics	0.18	34.46	34.46
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
PRGO Perrigo	1.31	2.32	1.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
MLYS Mineralys Therapeutics	84.46%
PBH Prestige Consumer Healthcare	99.95%
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
MLYS Mineralys Therapeutics	18.94%
PBH Prestige Consumer Healthcare	1.50%
PRGO Perrigo	0.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	147	125.51 million	116.97 million	Optionable
MLYS Mineralys Therapeutics	76	88.41 million	71.66 million	Optionable
PBH Prestige Consumer Healthcare	890	47.38 million	46.66 million	Optionable
PRGO Perrigo	8,100	138.77 million	138.21 million	Optionable

AQST, MLYS, PBH, and PRGO Headlines

Recent News About These Companies

Perrigo (NYSE:PRGO) Cut to Buy at Wall Street Zen

September 27 at 1:07 AM | americanbankingnews.com

Perrigo (NYSE:PRGO) Stock Moved Down to Buy by Wall Street Zen

September 27 at 1:05 AM | marketbeat.com

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

September 25 at 8:35 AM | zacks.com

Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO

September 25 at 3:28 AM | marketbeat.com

Perrigo (NYSE:PRGO) Stock Price Up 5.9% - Should You Buy?

September 24 at 11:59 AM | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Given Average Rating of "Hold" by Brokerages

September 23, 2026 | americanbankingnews.com

Contrasting Pfizer (NYSE:PFE) & Perrigo (NYSE:PRGO)

September 23, 2026 | americanbankingnews.com

Perrigo (NYSE:PRGO) Stock Rating Upgraded by Wall Street Zen

September 19, 2026 | americanbankingnews.com

Perrigo (NYSE:PRGO) Upgraded at Wall Street Zen

September 19, 2026 | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Receives Consensus Rating of "Hold" from Analysts

September 18, 2026 | marketbeat.com

Perrigo (NYSE:PRGO) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

September 12, 2026 | marketbeat.com

Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?

September 4, 2026 | zacks.com

Zacks Research Has Negative Estimate for Perrigo Q1 Earnings

August 28, 2026 | marketbeat.com

Perrigo to Attend the Barclays Global Consumer Conference

August 27, 2026 | prnewswire.com

PRGO or NEOG: Which Is the Better Value Stock Right Now?

August 26, 2026 | zacks.com

Should Value Investors Buy Perrigo (PRGO) Stock?

August 26, 2026 | zacks.com

Perrigo Company plc

August 24, 2026 | money.usnews.com

This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.

August 22, 2026 | fool.com

Perrigo Co. PLC stock underperforms Tuesday when compared to competitors despite daily gains

August 19, 2026 | marketwatch.com

Perrigo Earnings Call Balances Pressure and Progress

August 16, 2026 | tipranks.com

Perrigo: The Rebound Is Just Getting Started

August 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, MLYS, PBH, and PRGO Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.68 -0.14 (-2.90%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.78 +0.10 (+2.14%)

As of 09/25/2026 07:44 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Mineralys Therapeutics NASDAQ:MLYS

$25.86 -0.73 (-2.75%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$25.86 +0.00 (+0.02%)

As of 09/25/2026 07:30 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Prestige Consumer Healthcare NYSE:PBH

$46.51 +0.86 (+1.89%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$46.60 +0.09 (+0.20%)

As of 09/25/2026 07:30 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Perrigo NYSE:PRGO

$15.43 +0.75 (+5.08%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$15.40 -0.03 (-0.17%)

As of 09/25/2026 07:55 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, MLYS, PBH, and PRGO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, MLYS, PBH, and PRGO Earnings

Compare Dividends

Latest AQST, MLYS, PBH, and PRGO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, MLYS, PBH, and PRGO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, MLYS, PBH, and PRGO Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Mineralys Therapeutics NASDAQ:MLYS

Prestige Consumer Healthcare NYSE:PBH

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, MLYS, PBH, and PRGO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, MLYS, PBH, and PRGO Earnings

Compare Dividends

Latest AQST, MLYS, PBH, and PRGO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, MLYS, PBH, and PRGO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, MLYS, PBH, and PRGO Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Mineralys Therapeutics NASDAQ:MLYS

Prestige Consumer Healthcare NYSE:PBH

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools